Thursday, April 20, 2017 4:14:11 PM
IMNP @ Stockcharts
CEO Tepper has got some game left with his play given today' news and the stock up 49% / 19M shares trading / closing at $3.65.
Took a ton of profit today and will come back as I believe their is more room for growth in 2017/2017.
Immune Pharma's stock rockets on heavy volume after license pact
http://www.marketwatch.com/story/immune-pharmas-stock-rockets-on-heavy-volume-after-license-pact-2017-04-20
PINT PHARMA:
Pint was established in 1993 as a spinout of the University of Austria. Initially focused on marketing prostaglandins, which it still sells under its own brand, Pint has since built a portfolio of in-licensed and internally developed drugs for oncology, rare disease, and specialty pharma indications.
Pint has direct commercial operations in Colombia, Mexico, Brazil, Venezuela, Peru, and the Dominican Republic.
“Adding Ceplene to our portfolio of products will further leverage our experience and presence in the oncology field in Latin America," added Pint CEO David Muñoz.
http://www.genengnews.com/gen-news-highlights/immune-pharma-licenses-cancer-treatments-latin-america-rights-to-pint/81254226
Investor 100
CEO Tepper has got some game left with his play given today' news and the stock up 49% / 19M shares trading / closing at $3.65.
Took a ton of profit today and will come back as I believe their is more room for growth in 2017/2017.
Immune Pharma's stock rockets on heavy volume after license pact
http://www.marketwatch.com/story/immune-pharmas-stock-rockets-on-heavy-volume-after-license-pact-2017-04-20
PINT PHARMA:
Pint was established in 1993 as a spinout of the University of Austria. Initially focused on marketing prostaglandins, which it still sells under its own brand, Pint has since built a portfolio of in-licensed and internally developed drugs for oncology, rare disease, and specialty pharma indications.
Pint has direct commercial operations in Colombia, Mexico, Brazil, Venezuela, Peru, and the Dominican Republic.
“Adding Ceplene to our portfolio of products will further leverage our experience and presence in the oncology field in Latin America," added Pint CEO David Muñoz.
http://www.genengnews.com/gen-news-highlights/immune-pharma-licenses-cancer-treatments-latin-america-rights-to-pint/81254226
Investor 100
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
